Effect of Gonadotropin-Releasing Hormone Agonist Pre-Treatment on Outcomes of Fresh and Frozen Embryo Transfers in Women With Adenomyosis: A Retrospective Cohort Study With Literature Review

Li X, Xin Li, Yixin Li, Li Y, Hexiang Peng, Peng H, Mengying Wang, Wang M, Yuqi Liu, Liu Y, Wu T, Tao Wu, Xue Q, Qing Xue
BJOG: An International Journal of Obstetrics & Gynaecology · 2024 · vol. 132(S2) , pp. 62–74 · doi:10.1111/1471-0528.18026 · PMID:39688600 · W4405497635
Systematic review / meta-analysis OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study found that gonadotropin-releasing hormone agonist pre-treatment was associated with higher live birth rates in women with adenomyosis undergoing fresh and frozen embryo transfers.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To investigate the effect of gonadotropin-releasing hormone agonist (GnRHa) pre-treatment on the clinical outcomes of fresh and frozen embryo transfers (ETs and FETs, respectively) in infertile patients with adenomyosis. DESIGN: Retrospective cohort study with literature review. SETTING: Peking University First Hospital. POPULATION: We analysed 413 cycles of 369 women with adenomyosis who underwent ETs or FETs. METHODS: We performed logistic regression analysis and meta-analysis to assess the association of GnRHa pre-treatment with the clinical outcomes of ETs and FETs. MAIN OUTCOME MEASURES: The live birth rate (LBR) was compared between patients with and without GnRHa pre-treatment. RESULTS: The LBR was higher in the GnRHa pre-treatment group than in the non-GnRHa pre-treatment group in ETs (41.27% vs. 24.32%, p = 0.034) and FETs (40.36% vs. 20.75%, p = 0.008). The odds of achieving a live birth of women with GnRHa pre-treatment were 2.65 times higher than that of those without (95% CI: 1.19-5.92, p = 0.017) after adjusting for confounders in ETs. Similarly, the adjusted odds ratio (OR) was 2.43 (95% CI: 1.10-5.40, p = 0.029) in FETs. For the meta-analysis, eight studies met the inclusion criteria; however, only six reported the adjusted ORs. Combination of these six adjusted ORs with our results revealed that the GnRHa pre-treatment group had higher LBRs than the non-GnRHa pre-treatment group (ET: OR 1.71, 95% CI: 1.30-2.26, FET: OR 2.61, 95% CI: 1.52-4.49). CONCLUSIONS: In women with adenomyosis, GnRHa pre-treatment may be beneficial for LBRs following both ETs and FETs.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (44)

Cited by (2)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-16T06:06:37.907988+00:00
unpaywall
last seen: 2026-10-16T06:24:35.758740+00:00
License: CC0 · commercial use OK